|
Session 127
Poster Abstracts
Pharmacokinetics, Safety, and Efficacy of ART in Infants, Children, and Adolescents
Tuesday, 1 - 4 pm
Poster Hall |
| 715 |
The PACTG 1020A Protocol: Atazanavir with or without Ritonavir in HIV-infected Infants, Children, and Adolescents
Richard Rutstein*1, P Samson2, J Kiser3, C Fletcher3, B Graham4, S Schnittman5, M Smith6, L Mofenson6, T Fenton2, G Aldrovandi7, and the PACTG 1020A Study Team
1Children's Hosp of Philadelphia, PA, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Univ of Colorado Hlth Sci Ctr, Denver, US; 4Frontier Sci & Tech Res Fndn, Amherst, NY, US; 5Bristol-Myers Squibb, Wallingford, CT, US; 6NIH, Bethesda, MD, US; and 7Children's Hosp Los Angeles, CA, US |
716
 |
Pharmacokinetics and 24-Week Efficacy and Safety of Lopinavir/Ritonavir in HIV-1-infected Infants <6 Weeks of Age
Jorge Pinto*1, B Robbins2, J Chen3, L Serchuck4, E Capparelli5, R Yogev6, P Palumbo7, J Rodman2, B Heckman8, E Chadwick6, and PACTG P1030 Team of Investigators
1Federal Univ of Minas Gerais, Belo Horizonte, Brazil; 2St Jude Children's Res Hosp, Memphis, TN, US; 3Harvard Sch of Publ Hlth, Boston, MA, US; 4Natl Inst of Child Hlth and Human Devt, NIH, Bethesda, MD, US; 5Univ of California, San Diego, US; 6Feinberg Sch of Med, Northwestern Univ, Chicago, IL, US; 7Dartmouth Med Sch, Hanover, NH, US; and 8Frontier Sci & Tech Res Fndn, Amherst, NY, US |
| 717 |
Pharmacokinetics of High-dose Lopinavir/Ritonavir with and without Saquinavir or NNRTI in HIV-infected Pediatric and Adolescent Patients Previously Treated with PI
Brian Robbins*1, P Havens2, E Capparelli3, E Chadwick4, R Yogev5, L Serchuck6, C Worrell7, C Alvero8, B Heckman9, J Rodman1, and PACTG 1038 Team
1St Jude Children's Res Hosp, Memphis, TN, US; 2Med Coll of Wisconsin, Children's Res Inst, Milwaukee, US; 3Univ of California, San Diego, US; 4Northwestern Univ, Chicago, IL, US; 5Children's Memorial Hosp, Northwestern Univ, Chicago, IL, US; 6Natl Inst of Child Hlth and Human Devt, NIH, Rockville, MD, US; 7Div of AIDS, NIAID, NIH, Bethesda, MD, US; 8Statistical & Data Analysis Ctr, Harvard Sch of Publ Hlth, Boston, MA, US; and 9Frontier Sci & Tech Res Fndn, Amherst, NY, US |
| 718 |
Safety and Antiviral Activity of Fosamprenavir-containing Regmens in HIV-infected 2- to 18-Year-Old Pediatric Subjects (Interim Data, Study APV29005)
Coleen Cunningham*1, A Freedman2, S Read3, D Duiculescu4, E Voronin5, I De Jose6, D Perez-Tamarit7, A Carrod8, J Yeo8, and H Garges9
1Duke Univ Med Ctr, Durham, NC, US; 2New York Weill Cornell Med Ctr, NY US; 3Hosp for Sick Children, Toronto, Canada; 4Spitalul Clin de Boli Infectioase si Tropicale “Victor Babes”, Bucharest, Romania; 5St Petersburg Republic Hosp of Infectious Disease, Russia; 6Hosp Infantil la Paz, Madrid, Spain; 7Hosp Infantil la Fe, Valencia, Spain; 8GlaxoSmithKline, Greenford, UK; and 9GlaxoSmithKline, Research Triangle Park, NC, US |
| 719 |
Safety and Antiviral Activity of Fosamprenavir/Ritonavir Once Daily Regimens in HIV-infected Pediatric Subjects Ages 2 to 18 Years (48-Week Interim Data, Study APV20003)
Ellen Chadwick*1, W Borkowsky2, C Fortuny3, J Leon Leal4, M Neves5, N Hartwig6, G Castelli Gattinara7, N Givens8, C Garris9, and I Gray9
1Children's Memorial Hosp, Chicago, IL, US; 2New York Univ Med Ctr, NY, US; 3Hosp San Juan de Dios, Barcelona, Spain; 4Hosp Infantil Virgen del Rocio, Sevilla, Spain; 5Hosp Fernando Fonseca, Amadora, Portugal; 6Sophia Childrens Hosp, Rotterdam, The Netherlands; 7Bambino Gesu Children's Hosp, Rome, Italy; 8GlaxoSmithKline, Greenford, UK; and 9GlaxoSmithKline, Research Triangle Park, NC, US |
| 720 |
Tenofovir DF Salvage Therapy in HIV-infected Children and Further Studies on Bone Mineral Density
J Purdy1, R Gafni1,2, R Gafni1,2, S Zeichner1,3, S Zeichner1,3, and Rohan Hazra*1
1NCI, NIH, Bethesda, MD, US; 2Univ of Maryland Med Systems, Baltimore, US; and 3Children's Natl Med Ctr, Washington, DC, US |
721
|
Non-linear Pharmacokinetics of High-dose Recombinant Fusion Protein CD4-IgG2 Observed in HIV-1-infected Children
W Shearer1, J DeVille2, P Samson3, J Moye4, J Church5, H Spiegel6, T Fenton3, M Smith7, B Graham8, Courtney V. Fletcher*9, and Pediatric AIDS Clinical Trials Group, National Institutes of Health, Bethesda, MD, USA
1Baylor Coll of Med, Houston, TX, US; 2Univ of California, Los Angeles, US; 3Statistical & Data Analysis Ctr, Harvard Sch of Publ Hlth, Boston, MA, US; 4Natl Inst of Child Hlth and Human Devt, NIH, Bethesda, MD, US; 5Keck Sch of Med, Children's Hosp Los Angeles and Univ of Southern California, US; 6Children's Natl Med Ctr, Washington, DC, US; 7NIAID, NIH, Bethesda, MD, US; 8Frontier Sci & Tech Res Fndn, Amherst, NY, US; and 9Univ of Colorado Hlth Sci Ctr, Denver, US |
|
